Attached files
| file | filename |
|---|---|
| EX-4.1 - EXHIBIT 4.1 DESCRIPTION OF CAPITAL STOCK - VOLITIONRX LTD | f10k123119_ex4z1.htm |
| 10-K - FORM 10-K ANNUAL REPORT - VOLITIONRX LTD | f10k123119_10k.htm |
| EX-32.1 - EXHIBIT 32.1 SECTION 906 CERTIFICATION - VOLITIONRX LTD | f10k123119_ex32z1.htm |
| EX-31.2 - EXHIBIT 31.2 SECTION 302 CERTIFICATION - VOLITIONRX LTD | f10k123119_ex31z2.htm |
| EX-31.1 - EXHIBIT 31.1 SECTION 302 CERTIFICATION - VOLITIONRX LTD | f10k123119_ex31z1.htm |
| EX-21.1 - EXHIBIT 21.1 SUBSIDIARIES OF VOLITIONRX LIMITED - VOLITIONRX LTD | f10k123119_ex21z1.htm |
| EX-10.22 - EXHIBIT 10.22 AMENDMENT NO. 1 TO CLINICAL STUDY AGREEMENT - VOLITIONRX LTD | f10k123119_ex10z22.htm |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Audit Committee
VolitionRx Limited
As independent registered public accountants, we hereby consent to the incorporation by reference of our report dated February 20, 2020, contained in this annual report on Form 10-K with respect to the consolidated financial statements of VolitionRx Limited, in its registration statements on Form S-3 (Registration Statement Nos. 333-195213, 333-227248, 333-227731 and 333-236335) and its registration statements on Form S-8 (Registration Statement Nos. 333-208512, 333-214118, 333-221054, 333-227565 and 333-236336).
/s/ Sadler Gibb & Assoc.
Sadler, Gibb & Associates, LLC
Salt Lake City, UT
February 20, 2020
